Major pharmaceutical companies are significantly expanding their manufacturing and research presence in the United States, with companies including Pfizer, Eli Lilly, Johnson & Johnson, Roche, AstraZeneca and Novartis announcing investments that together approach $500 billion.
The investments cover new manufacturing facilities, research and development centers, supply-chain infrastructure and expansions of existing sites. The moves come as pharmaceutical companies face increasing pressure to manufacture more medicines domestically and reduce their reliance on overseas production.
Pfizer has committed $70 billion toward U.S. research and domestic manufacturing, while Eli Lilly has announced plans for multiple new manufacturing facilities. Johnson & Johnson plans to increase its U.S. investment to $55 billion over the next four years, while AstraZeneca has committed $50 billion through 2030.
European companies are also expanding substantially. Roche has pledged more than $50 billion, Novartis plans to invest $23 billion across 10 U.S. sites, and Sanofi has committed at least $20 billion through 2030.
The scale of the investments highlights how trade policy, supply-chain resilience and pharmaceutical manufacturing are increasingly influencing corporate strategy. Building domestic capacity is also likely to reshape where medicines and pharmaceutical ingredients are produced in the coming years.
